164 P. Bystro¨m et al. should have inferior outcome, i.e. with malnutri- tion etc. It could also be explained with a statistical mass effect. Based on the results from this study, it is not clinically relevant to tailor treatment for individual ACRC patients based on B12, folate, or homocys- teine levels. Most likely the individual patients gain more if we tailor treatment with respect to more established predictive markers for toxicity and treat- ment effect, like dihydropyrimidine dehydrogenase (DPD), TS, and Thymidine phosphorylase (TP) levels when treating with antifolates. Declaration of interest: The authors report no conﬂicts of interest. The authors alone are respon- sible for the content and writing of the paper. References 1. Duthie SJ, Narayanan S, Sharp L, Little J, Basten G, Powers H. Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc. 2004;63:571 8. 2. Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med. 2001;138:164 76. 3. Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, Melton LJ 3rd. Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med. 1989;111:738 42. 4. Prinz-Langenohl R, Fohr I, Pietrzik K. Beneﬁcial role for folate in the prevention of colorectal and breast cancer. Eur J Nutr. 2001;40:98 105. 5. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med. 1998;129:517 24. 6. Kim YI. Will mandatory folic acid fortiﬁcation prevent or promote cancer? Am J Clin Nutr. 2004;80:1123 8. 7. Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nat Clin Pract Oncol. 2009;6:17 24. 8. Bunn P, Paoletti P, Niyikiza C, Rusthoven J, Nelson K, Hanauske AR, et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, Ly231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol. 2001;20: 76a (abstr 300). 9. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol. 2008;19:909 14. 10. Bjorkegren K, Svardsudd K. Serum cobalamin, folate, methylmalonic acid and total homocysteine as vitamin B12 and folate tissue deﬁciency markers amongst elderly Swedes*a population-based study. J Intern Med. 2001;249: 423 32. 11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organiza- tion for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205 16. 12. Glimelius B. Biochemical modulation of 5-ﬂuorouracil: A randomized comparison of sequential methotrexate, 5-ﬂuor- ouracil and leucovorin versus sequential 5-ﬂuorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol. 1993;4:235 41. 13. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche´ O, Etienne PL, et al. Randomized trial comparing monthly low- dose leucovorin and ﬂuorouracil bolus with bimonthly high- dose leucovorin and ﬂuorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808 15. 14. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-ﬂuorour- acil and folinic acid Nordic schedule as ﬁrst-line therapy in advanced colorectal cancer. Ann Oncol. 2002;13:1868 73. 15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with ﬂuorouracil compared with ﬂuorouracil alone as ﬁrst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041 7. 16. National Cancer Institute. National Cancer Institute com- mon toxicity criteria. Available at: http://ctep.cancer.gov/ reporting/ctc.html. 17. Calvert H. Folate status and the safety proﬁle of antifolates. Semin Oncol. 2002;29:3 7. 18. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1:545 52. 19. van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efﬁcacy of thymidy- late synthase inhibitors. Cancer Res. 2001;61:3675 81. 20. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653 64. 21. Ho C, Ng K, O’Reilly S, Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer. 2005;5: 279 82. 22. Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of ﬁxed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer. 2006;94:964 8. 23. Lokich J. Capecitabine: ﬁxed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest. 2004;22:713 7.